Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea

NCT05071612 is registered in ClinicalTrials.gov with Apnimed as lead sponsor.

NCT NCT05071612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05071612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea
Lead sponsor
Apnimed
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2021
Completion date
August 3, 2022
Enrollment
294 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

osa - obstructive sleep apnea